Verona Pharma plc (VRNA) is all set to announce results from its phase IIb dose-ranging study evaluating nebulized Ensifentrine as an add-on to treatment with a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease on Monday, January 13, 2020, at 5.00 am GMT.
from RTT - Biotech https://ift.tt/39XFHMJ
via IFTTT
No comments:
Post a Comment